Skip to main content
Premium Trial:

Request an Annual Quote

Tissue Microarrays Part of Metamark Genetics' Cancer Diagnostics Efforts


By Justin Petrone

Cancer diagnostics startup Metamark Genetics is using tissue microarrays to develop assays that will guide treatment for cancer patients.

A company spokesperson told BioArray News last week that the Cambridge, Mass.-based firm is using TMAs, as well as other technologies, as part of its effort to develop its Prognosis Determinants system. The spokesperson declined to discuss what other technologies are being used in the system.

Metamark has identified and validated functionally active genetic determinants of metastasis "critical to the progression of a broad spectrum of tumor types," according to its website. The company is developing diagnostic assays based on its discoveries.

Some of the firm's co-founders and personnel have experience with TMA technology. Co-founder David Rimm, who is a consultant to the company, is director of the Yale Tissue Microarray Facility.

Metamark disclosed last week in a filing with the US Securities and Exchange Commission that it raised about $22 million in a Series B round of financing. The company is targeting about $42 million in total, it said. Among the participants in the round were directors and executives at the Cambridge, Mass.-based firm, which said that it intends the offering to last more than one year. It is not related to a business combination transaction, such as a merger, acquisition, or exchange offer, Metamark said in its filing.

Metamark said in a statement released last week that the lead investor in the round has an obligation to purchase up to an aggregate of $8 million of additional preferred stock. Proceeds will be used to expand Metamark's research and development efforts and clinical testing infrastructure, and establish its commercial organization, the firm said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.